Pascal Brandys
Chief Executive Officer at Phylex Biosciences, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Yochi Slonim | M | - |
Anima Biotech, Inc.
 Anima Biotech, Inc. Pharmaceuticals: MajorHealth Technology Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ. | - |
| Agnes Le Saux-Narjoz | F | - |
Serono Genetics Institute SA
 Serono Genetics Institute SA Miscellaneous Commercial ServicesCommercial Services Part of Merck KGaA, Serono Genetics Institute SA is a French biotechnology company specializing in synthetic DNA and genetic analysis. The company is based in Paris, France. The company was founded in 1989 by Pascal Brandys. Serono Genetics Institute was acquired by Serono SA on September 23, 2002 for $65.82 million.
Phylex Biosciences, Inc.
 Phylex Biosciences, Inc. BiotechnologyHealth Technology Phylex Biosciences, Inc. operates as a biotechnology company. The company is headquartered in Del Mar, CA. | 16 years |
| Zeev Smilansky | M | - |
Anima Biotech, Inc.
Anima Biotech, Inc. Pharmaceuticals: MajorHealth Technology Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ. | 19 years |
| Roger I. Pennell | M | 64 | 26 years | |
| Shawn Barnett | M | - | 8 years | |
| Avi Eliassaf | M | - |
Anima Biotech, Inc.
Anima Biotech, Inc. Pharmaceuticals: MajorHealth Technology Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ. | - |
| Gilead Sher | M | 71 |
Anima Biotech, Inc.
Anima Biotech, Inc. Pharmaceuticals: MajorHealth Technology Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ. | - |
| Barak Ben-Eliezer | M | 49 |
Anima Biotech, Inc.
Anima Biotech, Inc. Pharmaceuticals: MajorHealth Technology Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Richard Hamilton | M | 61 | 20 years | |
| Cheryl Morley | F | 69 | 5 years | |
| Gerard van Acker | M | 81 | 3 years | |
| Richard B. Flavell | M | 80 | 18 years | |
| François Amalric | M | - |
Endocube SAS
 Endocube SAS Pharmaceuticals: MajorHealth Technology Endocube SAS specializes in identification, validation and selection of novel drugable targets. The firm offers its services for the diagnosis and treatment of major chronic inflammatory conditions. The company was founded Pascal Brandys and Agnès Le Saux-Narjoz in 2001 and is headquartered in Labège, France. | 11 years |
| Steven C. Bobzin | M | - | - | |
| Douglas Suttles | M | 63 | 2 years | |
| Ruth Devenyns | F | 59 | - | |
| Gary Koppenjan | M | - | 10 years | |
| Steven Elliott Koonin | M | 72 | 3 years | |
| Aflalo Guimarães | M | 54 | 2 years | |
| Thomas D. Kiley | M | 80 | 13 years | |
| Wilfriede van Assche | F | 69 | 16 years | |
| Daniel Glat | M | 67 | 2 years | |
| Edmund Olivier | M | 86 | 18 years | |
| Ray Debbane | M | 69 | 16 years | |
| Peter Mascia | M | - | - | |
| Walter Nelson | M | - | - | |
| Spencer Swayze | M | - | - | |
| Pierre Bougneres | M | - |
Endocube SAS
Endocube SAS Pharmaceuticals: MajorHealth Technology Endocube SAS specializes in identification, validation and selection of novel drugable targets. The firm offers its services for the diagnosis and treatment of major chronic inflammatory conditions. The company was founded Pascal Brandys and Agnès Le Saux-Narjoz in 2001 and is headquartered in Labège, France. | - |
| Frank Hardimon | M | - | - | |
| Michael Stephenson | M | 82 | 6 years | |
| J. Jefferson Gwyn | M | 65 | - | |
| Paul M. Kuc | M | 61 | 8 years | |
| Jean-Philippe Girard | M | 65 |
Endocube SAS
Endocube SAS Pharmaceuticals: MajorHealth Technology Endocube SAS specializes in identification, validation and selection of novel drugable targets. The firm offers its services for the diagnosis and treatment of major chronic inflammatory conditions. The company was founded Pascal Brandys and Agnès Le Saux-Narjoz in 2001 and is headquartered in Labège, France. | - |
| Gary McCone | M | 67 | 7 years | |
| Anna Rath | F | - | - | |
| John Bouck | M | - | - | |
| Patrick McCroskey | M | 61 | 1 years | |
| Floris Vansina | M | - | - | |
| Mark Vaeck | M | - | 3 years | |
| Luc Aguilar | M | - |
Endocube SAS
Endocube SAS Pharmaceuticals: MajorHealth Technology Endocube SAS specializes in identification, validation and selection of novel drugable targets. The firm offers its services for the diagnosis and treatment of major chronic inflammatory conditions. The company was founded Pascal Brandys and Agnès Le Saux-Narjoz in 2001 and is headquartered in Labège, France. | - |
| Philippe Rousseau | M | 53 |
Serono Genetics Institute SA
Serono Genetics Institute SA Miscellaneous Commercial ServicesCommercial Services Part of Merck KGaA, Serono Genetics Institute SA is a French biotechnology company specializing in synthetic DNA and genetic analysis. The company is based in Paris, France. The company was founded in 1989 by Pascal Brandys. Serono Genetics Institute was acquired by Serono SA on September 23, 2002 for $65.82 million. | - |
| Frank Bulens | M | 61 | - | |
| Philippe Jais | M | - |
Serono Genetics Institute SA
Serono Genetics Institute SA Miscellaneous Commercial ServicesCommercial Services Part of Merck KGaA, Serono Genetics Institute SA is a French biotechnology company specializing in synthetic DNA and genetic analysis. The company is based in Paris, France. The company was founded in 1989 by Pascal Brandys. Serono Genetics Institute was acquired by Serono SA on September 23, 2002 for $65.82 million. | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 37 | 86.05% |
| France | 7 | 16.28% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Pascal Brandys
- Personal Network
